BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rimegepant (Nurtec ODT) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rimegepant (Nurtec ODT)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06641466-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06641466)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Women When Used for 
 Intermittent Prevention of Menstrual Migraine\nEstimated primary completio
 n: 29 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06641466
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07835035-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Rimegepant (Nurtec ODT): Phase 1 readout est. (NCT07835035)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 1.\nStudy: Rimegepant Plus Tori
 palimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy
 \nEstimated primary completion: 28 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07835035
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918053-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rimegepant (Nurtec ODT): Phase na readout est. (NCT07918053)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase na\, Migraine.\nStudy: A Prospe
 ctive Study of Rimegepant for Short-term Preventive Treatment of Night-shi
 ft-related Migraine in Healthcare Professionals\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimeg
 epant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07918053
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667621-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rimegepant (Nurtec ODT): Phase 1 readout est. (NCT07667621)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 1\, Migraine.\nStudy: A Prospec
 tive\, Open-Label Study Evaluating the Effectiveness of Gepants for Acute 
 Treatment of Migraine in the Emergency Department\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rim
 egepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07667621
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871097-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rimegepant (Nurtec ODT): Phase 4 readout est. (NCT07871097)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 4\, Migraine.\nStudy: Acute Tre
 atment of Vestibular Migraine by Rimegepant\nEstimated primary completion:
  30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 megepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07871097
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751497-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rimegepant (Nurtec ODT): Phase 2 readout est. (NCT07751497)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2\, Migraine.\nStudy: A Randomi
 zed\, Open-Label\, Multi-Center Study of Vestibular Migraine Prevention: R
 imegepant Versus Flunarizine Non-inferiority Study\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07751497
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435090-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rimegepant (Nurtec ODT): Phase 2/3 readout est. (NCT07435090)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2/3.\nStudy: Efficacy and Safet
 y of Rimegepant for Acute Dizziness\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant
 -nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07435090
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685769-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280104
DTEND;VALUE=DATE:20280105
SUMMARY:Rimegepant (Nurtec ODT): Phase 4 readout est. (NCT07685769)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 4\, Migraine.\nStudy: A Study t
 o Find Out if the Medicine Called Rimegepant is Safe for Adults in India\n
 Estimated primary completion: 4 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07685769
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609914-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280607
DTEND;VALUE=DATE:20280608
SUMMARY:Rimegepant (Nurtec ODT): Phase 4 readout est. (NCT07609914)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 4\, Migraine.\nStudy: A Study t
 o Learn About the Safety of Taking an Additional Dose of the Medicine Rime
 gepant in Adults With Migraine\nEstimated primary completion: 7 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-od
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 609914
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729462-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281021
DTEND;VALUE=DATE:20281022
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT07729462)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adults When Used for
  the Prevention of Chronic Migraine\nEstimated primary completion: 21 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant-
 nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07729462
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812467-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rimegepant (Nurtec ODT): Phase 2 readout est. (NCT07812467)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2.\nStudy: Rimegepant-Sensitize
 d Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell C
 arcinoma\nEstimated primary completion: 31 October 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07812467
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613788-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Rimegepant (Nurtec ODT): Phase 2 readout est. (NCT07613788)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2.\nStudy: Rimegepant Plus Glof
 itamab and CD19 CAR-T Therapy in R/R LBCL\nEstimated primary completion: N
 ovember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegep
 ant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07613788
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475234-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rimegepant (Nurtec ODT): Phase 1/2 readout est. (NCT07475234)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 1/2.\nStudy: Rimegepant Combine
 d With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic D
 uctal Adenocarcinoma\nEstimated primary completion: December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07475234
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999252-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rimegepant (Nurtec ODT): Phase 2 readout est. (NCT06999252)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2.\nStudy: Rimegepant Combined 
 With PD-1 in Liver Metastasis Colorectal Cancer Patients\nEstimated primar
 y completion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06999252
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473597-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rimegepant (Nurtec ODT): Phase 4 readout est. (NCT06473597)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 4\, Migraine.\nStudy: A Compari
 son of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Hea
 dache\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06473597
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649242-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04649242)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Randomize
 d Study in Children and Adolescents With Migraine: Acute Treatment\nEstima
 ted primary completion: 9 January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04649242
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05156398-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT05156398)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Efficacy 
 and Safety Study of Rimegepant for the Preventative Treatment of Migraine 
 in Pediatric Subjects\nEstimated primary completion: 27 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05156398
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616194-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06616194)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adolescents With Fre
 quent Migraine\nEstimated primary completion: 26 February 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06616194
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743141-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04743141)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Long-term
  Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment 
 of Migraine\nEstimated primary completion: 31 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04743141
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795125-10363@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20310330
DTEND;VALUE=DATE:20310331
SUMMARY:Rimegepant (Nurtec ODT): Phase 2 readout est. (NCT07795125)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2.\nStudy: Rimegepant For Endom
 etriosis Pain\nEstimated primary completion: 30 March 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07795125
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
